Soegiarto Gatot, Mahdi Bagus Aulia, Wulandari Laksmi, Fahmita Karin Dhia, Hadmoko Satrio Tri, Gautama Hendra Ikhwan, Prasetyaningtyas Dewi, Prasetyo Muhammad Edwin, Negoro Pujo Prawiro, Arafah Nur, Purnomosari Dewajani, Tinduh Damayanti, Husada Dominicus, Baskoro Ari, Fetarayani Deasy, Nurani Wita Kartika, Oceandy Delvac
Division of Allergy and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga-Dr. Soetomo General Academic Hospital, Surabaya 60132, Indonesia.
Postgraduate School, Master Program on Immunology, Universitas Airlangga, Surabaya 60132, Indonesia.
Vaccines (Basel). 2023 Jun 26;11(7):1160. doi: 10.3390/vaccines11071160.
: The administration of the third (or booster) dose of COVID-19 vaccine is important in maintaining protection against SARS-CoV-2 infection or the severity of the disease. In Indonesia, health care workers (HCWs) are among the first to receive a booster dose of the COVID-19 vaccine. In this study, we evaluated the antibody response and adverse events following heterologous booster vaccine using mRNA-1273 among HCWs that were fully vaccinated with inactivated viral vaccine as the priming doses. : 75 HCWs at Dr. Soetomo General Hospital in Surabaya, Indonesia, participated in this study. The level of antibody against the SARS-CoV-2 receptor binding domain was analyzed at 1, 3, and 5 months following the second priming dose and at 1, 3, and 5 months after the booster dose. : We found a significantly higher level of antibody response in subjects receiving a booster dose of the mRNA-1273 vaccine compared to those receiving an inactivated viral vaccine as a booster. Interestingly, participants with hypertension and a history of diabetes mellitus showed a lower antibody response following the booster dose. There was a higher frequency of adverse events following injection with the mRNA-1273 vaccine compared to the inactivated viral vaccine, although the overall adverse events were considered minor. : A heterologous booster dose using mRNA vaccine resulted in a high antibody response; however, participants with hypertension and diabetes mellitus displayed a lower antibody response.
接种第三剂（或加强剂）新冠疫苗对于维持预防新冠病毒感染或减轻疾病严重程度至关重要。在印度尼西亚，医护人员是首批接种新冠疫苗加强剂的人群之一。在本研究中，我们评估了在以灭活病毒疫苗作为初始剂量完成全程接种的医护人员中，使用mRNA-1273进行异源加强疫苗接种后的抗体反应和不良事件。：印度尼西亚泗水苏托莫综合医院的75名医护人员参与了本研究。在第二剂初始剂量后的1、3和5个月以及加强剂量后的1、3和5个月，分析了针对新冠病毒受体结合域的抗体水平。：我们发现，与接受灭活病毒疫苗作为加强剂的受试者相比，接受mRNA-1273疫苗加强剂的受试者抗体反应水平显著更高。有趣的是，患有高血压和糖尿病病史的参与者在加强剂量后抗体反应较低。与灭活病毒疫苗相比，注射mRNA-1273疫苗后不良事件的发生率更高，不过总体不良事件被认为较轻。：使用mRNA疫苗进行异源加强剂量可产生较高的抗体反应；然而，患有高血压和糖尿病的参与者抗体反应较低。
